An open phase I study to assess the relationship between multiple doses of the MM120 solution to be ingested and subjective effects in healthy volunteers
Zusammenfassung der Studie
Mind Medicine Inc. (MindMed) is developing a form of D-Lysergsäurediethylamid (LSD) called MM120 for the treatment of generalized anxiety disorder (GAD). MM120 (LSD-D-Tartrate) is an ingestible hallucinogen. The sponsor has conducted three clinical studies with MM120. In a large-scale study, the efficacy of MM120 was demonstrated in patients with GAD. The purpose of the MM120-103 study is to assess the possibility of increasing the MM120 dose from 20 micrograms to 100 micrograms without changing the drug's effect. This study, which will be conducted at a single Swiss hospital, will enroll up to twenty healthy volunteers. During the study, participants will undergo clinical tests to ensure their eligibility for MM120 administration. This phase of the study is called screening. If everything is in order, participants will receive MM120 at the lowest dose. Depending on how well they tolerate the dose, they may receive higher doses of MM120. The study lasts up to 43 days, including 21 days for screening, up to 8 days for dosing, and 14 days for subsequent safety assessments. Based on the results of this study, follow-up studies will be conducted to examine whether MM120 continues to provide the same benefits when the perceptible effects of the drug are reduced.
(BASEC)
Untersuchte Intervention
Mind Medicine Inc. (MindMed) is developing a form of D-Lysergsäurediethylamid (LSD) called MM120 for the treatment of generalized anxiety disorder (GAD). MM120 (LSD-D-Tartrate) is an ingestible hallucinogen.
(BASEC)
Untersuchte Krankheit(en)
Only healthy volunteers are participating in this study. The development of the investigational drug MM120 aims to treat generalized anxiety disorder (GAD).
(BASEC)
1. At Visit 1: Participants aged 18 to 65 years inclusive. 2. Healthy, as determined by a physician (or designee) based on medical history and all eligibility assessments. 3. Suitable venous access for cannulation and repeated blood sampling. (BASEC)
Ausschlusskriterien
1. Women of childbearing potential who do not wish or cannot use a highly effective contraceptive method for the duration of the study (from screening to the last visit of the participant), OR Men who are physiologically capable of fathering a child and are sexually active with a woman of childbearing potential, but do not wish or cannot use a mechanical barrier method for contraception (e.g., condoms with or without spermicide cream or gel; the fertile partner must be asked to use a highly effective contraceptive method from screening to the last visit of the participant). 2. Women who are currently pregnant or breastfeeding or who wish to become pregnant or breastfeed during the study. 3. Sperm or egg donation or retrieval during the study. (BASEC)
Studienstandort
Basel
(BASEC)
Sponsor
Mind Medicine Inc. Stimolo Pharma Consulting GmbH
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Shelly Bustion
+41 79 2477143
sbustion@cluttermindmed.coMind Medicine Inc.
(BASEC)
Wissenschaftliche Auskünfte
nicht verfügbar
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Datum der Bewilligung durch die Ethikkommission
17.07.2024
(BASEC)
ICTRP Studien-ID
nicht verfügbar
Offizieller Titel (Genehmigt von der Ethikkommission)
A Phase 1, Open-label Study Evaluating Relationship Between Multiple Doses of MM120 Oral Solution and Subjective Effects in Healthy Volunteers (BASEC)
Wissenschaftlicher Titel
nicht verfügbar
Öffentlicher Titel
nicht verfügbar
Untersuchte Krankheit(en)
nicht verfügbar
Untersuchte Intervention
nicht verfügbar
Studientyp
nicht verfügbar
Studiendesign
nicht verfügbar
Ein-/Ausschlusskriterien
nicht verfügbar
nicht verfügbar
Primäre und sekundäre Endpunkte
nicht verfügbar
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
nicht verfügbar
Sekundäre IDs
nicht verfügbar
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
nicht verfügbar
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
mm120-103-lay-language-summary-de-ch.pdfLink zu den Ergebnissen im Primärregister
nicht verfügbar